SLIMS Users Can Now Connect to the iSpecimen Marketplace
Genohm and iSpecimen have jointly announced that Genohm has established a partnership with iSpecimen to enable users of the SLIMS laboratory information management system to seamlessly connect to the iSpecimen Marketplace.
The combined solution will allow Genohm customers to easily make their inventories of biospecimens and associated data available to researchers around the world through the marketplace, and then accept, fulfill and track associated orders for samples. These new capabilities enable Genohm customers to increase revenue as well as the utilization rates of their banked specimens.
The partnership, through the new iSpecimen Data Connector Programprovides Genohm with technology integration support to connect its SLIMS system to the iSpecimen Marketplace and marketing support to promote the joint solution to Genohm’s customers and prospects. Together, the combined solution adds new value to biorepositories and labs that use SLIMS by giving them a new way to spotlight their sample inventories more broadly and earn income from their use.
“Healthcare organizations like Genohm’s customers are doing the hard work of collecting biospecimens, so it should be quick and easy to make their samples available to researchers who need them,” said Christopher Ianelli, MD, PhD, Founder and CEO, iSpecimen. “Although joining the iSpecimen Marketplace has always been easy for specimen suppliers, Genohm’s participation in the iSpecimen Data Connector program makes technology integration virtually automatic.”
Increased specimen utilization will help Genohm customers make a bigger contribution to scientific progress and better fulfill the expectations of biospecimen donors. Meanwhile, researchers will gain quick access to a vast new network of healthcare organizations with hard-to-find, high-quality samples at the ready.
“Many of our clients have built prodigious specimen libraries with great untapped value for themselves and for science,” said Genohm CEO Frederik Decouttere. “The iSpecimen Marketplace Data Connector for SLIMS helps our clients quickly profit from the investments they’ve already made and expand their mission of contributing to scientific advancement.”
This article has been republished from materials provided by iSpecimen. Note: material may have been edited for length and content. For further information, please contact the cited source.
Artificial intelligence is having a positive impact on drug development and personalized medicine. With the ability to efficiently analyze small datasets that focus on the specific disease of interest, small dataset-based AI platforms can rationally design optimal drug combinations that are effective and based on real experimental data and not mechanistic assumptions or predictive modeling.READ MORE